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a  b  s  t  r  a  c  t
Different  iodinated  mouse  obestatin  peptides  have  been  characterized  toward  their  in vitro  stability  in the
main  metabolic  compartments  plasma,  liver  and  kidney.  Using  HPLC–UV  for quantiﬁcation,  signiﬁcant
differences  in  the  degradation  kinetics  of  the  iodinated  peptides,  arising  from  both  enzymatic  proteol-
ysis  and  dehalogenation,  were  found  when  compared  to the native,  unmodiﬁed  peptide.  HPLC–MS/MS
analysis  demonstrated  that  the  cleavage  sites  were  dependent  upon  the  biological  matrix  and  the loca-
tion of the  amino  acid residue  incorporating  the  iodine  atom(s).  The  degrading  proteases  were  found  to
target  peptide  bonds  further  away  from  the  iodine  incorporation,  while  proteolytic  cleavages  of  nearby
peptide  bonds  were  more  limited.  Diiodinated  amino  acid  residue  containing  peptides  were  found  ton vitro metabolic stability
roteases
eiodinases
eptidomimetics
be more  susceptible  to  deiodination  than  the  mono-iodinated  derivative.  In plasma,  the  percentage  of
peptide degradation  solely  attributed  to  deiodinase  activity  after  20 min  incubation  reached  up  to  25%  for
2,5-diiodo-H19-obestatin  compared  to 20%  and  only  3%  for (3,5-diiodo-Y16)- and  (3-iodo-Y16)  obestatin,
respectively.  Hence,  our  results  demonstrate  that  the  different  iodinated  peptides  pose  signiﬁcantly  dif-
ferent  metabolization  properties  and  thus,  also  different  biological  activities  are  expected  for  peptides
upon  iodination.
© 2011  Elsevier  Inc.  All rights  reserved.. Introduction
Obestatin is a recently discovered 23 amino acid peptide derived
rom the processing of the ghrelin gene, and has been claimed to
e a functional opponent of ghrelin (suppressing food intake) mak-
ng it a potential lead against obesity [32]. Although the in vivo
ctivity is increasingly being conﬁrmed by a number of research
roups [4,5,10,17,20],  many also failed to show inhibitory effects
n food and water intake [26]. Also, the underlying mechanism
till remains unclear as demonstrated by numerous contradic-
ory ﬁndings and a declaration by the discoverers of obestatin
Abbreviations: m-Obestatin, Mouse obestatin; 2,5-Diiodo-H, Diiodination on the
istidine amino acid residue; 2-Iodo-H, Monoiodination on the histidine amino
cid residue; 3,5-Diiodo-Y, Diiodination on the tyrosine amino acid residue; 3-
odo-Y, Monoiodination on the tyrosine amino acid residue; MIT, Monoiodinated
yrosine; DIT, Diiodinated tyrosine; MIH, Monoiodinated histidine; DIH, Diiodinated
istidine; ID or DI, Iodothyronine deiodinase; IYD, Iodotyrosine deiodinase; DIP, Di-
odinated peptide; MIP, Mono-iodinated peptide; NIP, Non-iodinated peptide; M,
roteolytic metabolite.
∗ Corresponding author. Tel.: +32 9 264 8100; fax: +32 9 264 8193.
E-mail address: Bart.DeSpiegeleer@UGent.be (B. De Spiegeleer).
196-9781/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
oi:10.1016/j.peptides.2011.12.010that even they cannot reproduce all their original ﬁndings with-
out paying attention to e.g. speciﬁc (circadian) time-effects [31].
In attempts to explain the conﬂicting results on obestatin, several
functional quality issues have been investigated in detail: pres-
ence of synthesis impurities in commercially available peptides [6]
and formation of mixtures during radio-iodination [27,28]. As for
most endogenous-derived peptide leads, obestatin has only little
resistance to systemic plasma and tissue proteases [29] which may
result in a failure to demonstrate convincing in vivo effects [30]. The
major in vitro plasma metabolic pathways of m-obestatin have been
shown to involve cleavage between residues F1 N2 and P4 F5,
with several other peptide bonds also being vulnerable to prote-
olytic activity (D6 V7, Y16 Q17, G20 R21, R21 A22 and A22 L23).
Currently, some recent studies investigated fragments or modi-
ﬁed obestatin derivatives to provide protection against enzymatic
degradation. Substitutions at G3 and G8 by -aminoisobutyric acid
and at F5 by cyclohexylalanine yielded promising insights into the
structural requirements [19], while pegylated obestatin was  found
to be three times more stable than native obestatin [2].  Using the
obestatin fragments {1–10} and {11–23}, some structure–activity
properties were deﬁned [24]. The inﬂuence of obestatin iodination
on its functional behavior, of which the enzymatic degradation is an
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mportant aspect, has not yet been described in detail for the differ-
nt possible derivatives (i.e. mono- and diiodinated on Y16 and H19),
lthough these iodinated obestatines are used throughout biomed-
cal studies. Moreover, the enzymatically catalyzed dehalogenation
f iodinated peptides has not yet been investigated, despite its
mportance.
The aim of the present study was to investigate the effect of
odine incorporation at Y16 and H19 on the resistance of m-obestatin
gainst in vitro degradation in the main biological tissues (plasma,
iver and kidney), encompassing proteolysis as well as deiodination.
hese data are not only important for the study of dehalogena-
ion of peptides in general, but also for the generation of new
eptidomimetics with improved stability characteristics and the
nterpretation of biomedical test results involving 125I-, 123I- or
31I-labeled peptides.
. Materials and methods
.1. Peptides and other materials
All peptides used (cf. Table 1) were of ≥95.0% peptide
urity, as veriﬁed by HPLC–UV analysis [6].  Unmodiﬁed mouse
bestatin was obtained from California Peptide Research (Napa,
A, USA). Iodinated mouse obestatin derivatives (i.e. (3-iodo-Y16)-
bestatin, (3,5-diiodo-Y16)-obestatin, (2,5-diiodo-H19)-obestatin
nd (3,5-diiodo-Y16, 2,5-diiodo-H19)-obestatin; all prepared using
moc-chemistry) were purchased from Bachem (Bubendorf,
witzerland). Heparinized NMRI mouse plasma and male ICR CD-
 mice were obtained from Harlan (Horst, Netherlands). Modiﬁed
owry Protein Assay Kit was purchased from Pierce Biotechnology
Rockford, IL, USA), and used according to the instructions of the
upplier. All other reagents were of analytical grade or better.
The following relative area response factors were calculated
or UV detection at 195/215 nm with reference to an equimolar
uantity of the native obestatin: 1.08/1.59, 1.14/1.80, 1.00/1.18 and
.11/1.77 for (3-iodo-Y16)-obestatin, (3,5-diiodo-Y16)-obestatin,
2,5-diiodo-H19)-obestatin and (3,5-diiodo-Y16, 2,5-diiodo-H19)-
bestatin, respectively. These values were used in the LC–UV
inetics.
.2. Preparation of homogenates
After cervical dislocation, mouse organs were cleaned and trans-
erred into ice-cold Krebs–Henseleit buffer pH 7.4 containing 0.2%
w/v) of d-glucose, followed by homogenization for approximately
 min  using a rotor–stator type homogenizer. After sedimentation
or 30 min  at 5 ◦C to remove the larger particles, the middle layer
as taken as ﬁnal homogenate, with aliquots stored at −35 ◦C until
urther use. Prior to use, the protein content of each homogenate
as determined using the Pierce Modiﬁed Lowry Protein Assay
ethod.
.3. In vitro metabolic stability testing
In vitro metabolic stability testing was determined using pre-
iously described procedures [30]. In brief, 90 g of peptide was
ncubated in Krebs–Henseleit buffer pH 7.4 with plasma/tissue
omogenate added (600 l of mouse plasma, 900 g of liver pro-
ein, or 300 g of kidney protein) at 37 ◦C while shaking. At
redetermined time intervals, aliquots were immediately trans-
erred into microtubes containing 1:10 volume of 10% (v/v) formic
cid solution in water. The enzyme reaction was stopped by heat-
ng at 95 ◦C for 5 min. Next, the sample is centrifuged to precipitate
he denatured proteins and collect the supernatant for subsequent
PLC analysis. Similarly, appropriate placebos, controls and refer-
nce solutions were prepared as well. Experiments were carriedes 33 (2012) 272–278 273
out in duplicates. Assuming ﬁrst-order kinetics, the rate constant
k was obtained from ln(Pt/Pt0 ) = −kt, from which the metabolic
half-life was determined as t1/2 = ln(2)/.
2.4. Liquid chromatography
The HPLC–PDA apparatus consisted of a Waters Alliance 2695
separations module, a Waters 2996 photodiode array detector
and a Waters 2475 multi-wavelength ﬂuorescence detector with
Empower 2 software for data acquisition (all Waters, Milford, MA,
USA). For PDA detection, the UV spectrum was recorded between
190 and 400 nm.
The HPLC–UV/MS apparatus consisted of a Spectra System
SN4000 interface, a Spectra System SCM1000 degasser, a Spec-
tra System P1000XR pump, a Spectra System AS3000 autosampler
and a Finnigan LCQ Classic ion trap mass spectrometer in posi-
tive ion mode (all Thermo, San José, CA, USA) equipped with a
Waters 2487 dual wavelength UV detector (Waters, Milford, MA,
USA) and XCalibur 2.0 software (Thermo, San José, CA, USA) for
data acquisition. From the total ion chromatogram (TIC), extracted
ion chromatograms (EICs) were obtained at selected m/z values.
Tandem mass spectrometry (MS/MS) data on obestatin peptides
and their metabolites were examined using SEQUEST® available in
BioWorks 3.3.1 software (Thermo, San José, CA, USA) based upon a
FASTA ﬁle containing the obestatin sequences.
HPLC analysis was performed using an Everest C18 238EV54
(250 mm × 4.6 mm I.D., 300 A˚, 5 m particle size) column (Grace
Vydac, Hesperia, CA, USA) in an oven set at 30 ◦C, with the follow-
ing solvent system: (A) 0.1% (w/v) formic acid in water, and (B) 0.1%
(w/v) formic acid in acetonitrile. The gradient used for the separa-
tion was: 95% A + 5% B from 0 to 5 min, followed a linear ramp from 5
to 65 min  going to 75% A + 25% B. The ﬂow rate was  set at 1.0 ml/min.
The percentage of dehalogenation at the 20 min  time point was esti-
mated using the LC–MS data from the (diiodo)-, (monoiodo)- and
(noniodo)-peptides, i.e. the non-proteolytic peptides only.
3. Results
Although iodine incorporation is considered to potentially
hinder peptide breakdown by protease activity, a statistically sig-
niﬁcant (i.e. based upon the 95% conﬁdence intervals) increase in
half-life time was  only observed for (3,5-diiodo-Y16)-obestatin in
plasma and for (3-iodo-Y16)-obestatin in liver homogenate (Fig. 1).
The in vitro ﬁrst-order degradation kinetic results obtained on
the different iodinated obestatin derivatives in different biolog-
ical matrices using UV detection at 195 nm are summarized in
Table 2. Tetra-iodinated obestatin did not give consistent quantita-
tive results due to excessive adsorption to containers and biological
matrices. Several obestatin metabolites arising from proteolytic
activity were observed using (tandem) mass spectrometry, being
above the limit of detection of 0.02% relative to the parent pep-
tide. Fig. 2 reﬂexes the relative importance of the different peptides
found, resulting from the cleavage of the indicated peptide bond
compared to the total quantity of degradants. For non-iodinated
mouse obestatin incubated in mouse plasma, liver and kidney (data
not shown), the obtained proteolytic fragments were consistent
with a previous study [29].
In addition to the proteolytic degradation, signiﬁcant dehalo-
genation was observed for the iodinated derivatives, especially
for (2,5-diiodo-H19)-obestatin incubated in plasma as depicted in
Fig. 3. From Table 3, it is obvious that iodine atom(s) removal in
plasma and liver homogenate increases in the following order: (3-
iodo-Y16)-, (3,5-diiodo-Y16)- and (2,5-diiodo-H19)-obestatin. The
percentage of peptide degradation solely attributed to deiodi-
nase activity after 20 min  incubation reached up to 25.5% for
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Table 1
Obestatin and its iodinated derivatives tested.
# Peptide Sequence Mr (g/mol)
1 Rat/mouse obestatin FNAPFDVGIKLSGAQYQQHGRAL-NH2 2516.82
2  (3-Iodo-Y16)-obestatin FNAPFDVGIKLSGAQI1YQQHGRAL-NH2 2642.72
3 (3,5-Diiodo-Y16)-obestatin FNAPFDVGIKLSGAQI2YQQHGRAL-NH2 2768.61
4  (2,5-Diiodo-H19)-obestatin FNAPFDVGIKLSGAQYQQI2HGRAL-NH2 2768.61
5 (3,5-Diiodo-Y16 2,5-Diiodo-H19)-obestatin FNAPFDVGIKLSGAQI2YQQI2HGRAL-NH2 3020.40
3,5
4,0
4,5
5,0
0 5 10 15 20
ln
(%
of
T 0
)
Incubation ti me  (min)
Unmodified mouse obestatin (3-Iodo-Tyr) mouse obestatin
Fig. 1. Time-dependent decrease of native and mono-iodinated Y16 mouse obestatin upon incubation in liver homogenate. Data are expressed as mean ± SEM.
Table  2
Half-life times of obestatin derivatives in biological matrices.
Peptide Half-life (min) [95% C.I.]
Plasma Liver homogenate Kidney homogenate
Mouse obestatin 16.8 [15.2, 18.7] 15.7 [13.5, 18.9] 7.0 [4.7, 13.9]
(3-Iodo-Y16)-obestatin 14.7 [11.2, 21.2] 41.5 [37.7, 46.3] 10.9 [8.8, 14.5]
(3,5-Diiodo-Y16)-obestatin 26.9 [20.9, 37.9] 14.2 [10.1, 24.1] 18.8 [12.0, 43.6]
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N(2,5-Diiodo-H )-obestatin 16.7 [11.4, 31.3] 
,5-diiodo-H19-obestatin in plasma, the remainder being prote-
lysis (34.5%) and intact peptide (40%). In liver, about half of
he quantity of dehalogenation products were formed compared
o plasma, attaining 11.2% for 2,5-diiodo-H19-obestatin, together
ith 43.1% proteolytic fragments and 45.7% of the parent peptide.
n vitro dehalogenation was also observed in kidney homogenate,
lthough to a much lesser extent when compared to plasma and
iver, being below 1%. However, because deiodination of prote-
lytic metabolites, nor proteolysis of deiodinated products, was
aken into account, the percentage deiodination is actually under-
stimated. The conceptual scheme is visualized in Fig. 4. Especially
hen the percentage of deiodination was found to be rather high,
everal metabolites arising from a combination of dehalogena-
ion and proteolysis were observed as well. This phenomenon is
able 3
ehalogenation: non-/mono-/diiodinated obestatin area % at T20 min using HPLC–MS and 
Peptide Plasma 
(3-Iodo-Y16)-ob 8.8/91.2/NA [3.1%] 
(3,5-Diiodo-Y16)-ob ND/24.1/75.9 [19.9%] 
(2,5-Diiodo-H19)-ob 18.9/20.2/60.9 [25.5%] 
A: not applicable; ND: not detectable as below the limit of detection, being 2.14 × 10−2%18.4 [13.6, 28.3] 13.2 [8.2, 35.0]
illustrated for (2,5-diiodo-H19)-obestatin in mouse plasma, which
was cleaved at the F5 D6 bond combined with the loss of a
single iodine atom, yielding DVGIKLSGAQYQQI1HGRAL-NH2. The
total ion chromatogram demonstrated a retention time of 31.1 min
for this proteolysis–dehalogenation product, showing three peaks
in the mass spectrum with M + 2H2+ = 1033.9, M + 3H3+ = 689.6 and
M + 4H4+ = 517.5. Its identity was further conﬁrmed using the (tan-
dem) mass spectrum (Fig. 5). This product may  originate from
two different pathways: (1) proteolysis of 2-iodo-H19-obestatin
obestatin (i.e. dehalogenation followed by proteolysis) or (2)
5 6deiodination of the F D metabolite fragment, which was ﬁrst
formed from (2,5-diiodo-H19)-obestatin. Both in plasma and liver
homogenate, the peptide bond between F5 and D6 was found to be
more susceptible to proteolytic cleavage for the iodinated peptide
percentage estimated.
Liver homogenate Kidney homogenate
2.6/97.4/NA [2.0%] ND/100.0/NA [0.0%]
0.5/7.9/91.6 [7.1%] ND/1.8/98.2 [0.86%]
0.3/19.4/80.3 [11.2%] ND/1.9/98.1 [0.47%]
.
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Fig. 2. Graphical overview of the proteolytic cleavages observed in plasma and liver homogenate. The relative importance was based on the total amount metabolites
o Q = 0.0
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pbserved and subdivided in four classes: (1) below the limit of quantiﬁcation (i.e. Lo
ompared to the native peptide. In plasma, the relative impor-
ance of this cleavage compared to the total degradants rises from
.5% in mouse obestatin to 23.5% for (3-iodo-Y16)-obestatin and
urther to about 49% and 34% in (3,5-diiodo-Y16)- and (2,5-diiodo-
19)-obestatin, respectively. Moreover, in plasma, the abundance
f cleavages near the C-terminus of the sequence (i.e. L11 L23) was
ound to generally decrease upon peptide iodination, except for
he R21 A22 bond, which actually increases upon iodination: 9.1%
n unmodiﬁed obestatin to 30.8, 2.8 and 32.3% in the different iod-
nated derivatives. In liver, a similar effect was observed, together
ith an inhibition of the A14 Q15 peptide bond proteolysis forhe iodinated obestatin derivatives. The observed deiodination of
bestatin was  the result of an enzymatic catalysis, and thus not
hemically driven, since the chemical control (i.e. incubation of
eptide in buffer) did not reveal any presence of deiodinated nor7%), –, (2) between LoQ and 10%, - - -, (3) between 10–30% — and (4) above 30% —.
oxidated obestatin peptides. Moreover, in the tissue metaboliza-
tion samples, no oxidative deiodination products could be observed
using EIC-LC–MS.
4. Discussion
Upon comparison of the in vitro stability of mouse obestatin
and its iodinated derivatives in different biological media, cleav-
age by proteolytic enzymes was found to be less pronounced for
the iodinated peptide. The main enzymes responsible for the pro-
duction of the metabolites were found to be pepsin, proteinase K,
chymotrypsin and thermolysin, belonging to the pepsin A1 family,
subtilisin S8, trypsin S1 family and thermolysin M4  family, respec-
tively [1,22].  The ﬁrst three enzymes prefer to cleave after aromatic
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tig. 3. Typical extracted ion HPLC–MS chromatogram (m/z = 881 and 923, respec
bestatin after incubation for 20 min  in mouse plasma. Peaks at 44.7, 48.6 and 51.5
mino acids (e.g. Y, W or F) which ﬁt in the hydrophobic pocket of
he enzyme. Other amino acids are targeted as well, but at a much
ower rate.
Apparently, the relevant proteases are negatively inﬂuenced in
heir catalytic hydrolysis by the supplementary iodine atom(s), but
his protease inhibition was compensated by additional dehalo-
enase activity. This latter phenomenon was found to be mainly
ssociated with plasma and liver, and more strongly affecting
he two diiodinated peptides. Our ﬁndings show that the diiodo-
yrosine amino acid residue is more susceptible to dehalogenation
han monoiodo-tyrosine, independent of the biological matrix.
oreover, (2,5-diiodo-H19)-obestatin was more rapidly dehalo-
enated compared to (3,5-diiodo-Y16)-obestatin.
The presence of such diiodinated species upon obestatin radio-
odination may  thus give rise to erroneous or even false negative
esults when used for certain in vitro (e.g. receptor binding) and
n vivo (e.g. distribution/imaging, blood–brain–barrier transport,
etabolic stability) studies.
Iodine, a scarce micronutrient, is actively salvaged in vertebrates
rom metabolized compounds for the biosynthesis of thyroid hor-
ones which are essential for normal brain development, growth
nd metabolism [16]. Enzymatic deiodination of mono- and diiod-
nated tyrosine and histidine amino acids (MIT, DIT, MIH  and DIH,
espectively) has been reported to occur both in vitro and in vivo
8,23], with excretion of these iodinated compounds being indica-
ive for certain thyroidal disorders [9,16].  To our best knowledge,
o direct measurement of in vitro peptide deiodination, yielding
xtensive sequence information on the metabolites formed has
een published yet. Dehalogenation of MIT  by thyroid iodotyro-
ine deiodinase (IYD) was reported to be faster than that of DIT
23], and requires a bound ﬂavin mononucleotide (FMN) for its
DIP MIP NIP
M(DI P) M(MI P) M(NIP)
ProteolysisProteolysis Proteolysis
DH
DH DH
DH
ig. 4. Schematic presentation of the concept of metabolization, dehalo-
enation as well as combinations of these processes in iodinated peptides.
IP  = diiodinated peptide, MIP  = monoiodinated peptide, NIP = noniodinated pep-
ide, DH = dehalogenation and M = proteolytic metabolite. showing dehalogenation of: (a) (3-iodo-Y16)-obestatin and (b) (3,5-diiodo-Y16)-
orrespond with non-, mono- and diiodinated peptide, respectively.
catalytic activity. In contrast, iodothyronine deiodinase (ID or DI)
requires an active-site Cys for reduced thyroxine generation [7].
These enzymes represent the most common two currently known
reductive dehalogenation pathways in mammals (Fig. 6), while
cytochrome systems were also described to dehalogenate in an
oxidative way  [3,11,12,14]. This latter enzyme was found not to be
responsible for the deiodination of obestatin derivatives because no
oxidated fragments were observed in the mass spectra of our sam-
ples. When comparing the substrate speciﬁcity of IYD to our results
on peptide-incorporated iodotyrosines, we demonstrated just the
opposite: a larger fraction dehalogenation of diiodo-tyrosine iodi-
nated peptide is obtained compared to that of monoiodo-tyrosine
iodinated peptide. This latter ﬁnding is thus not only considered
to be more consistent with an efﬁcient salvage of iodine atoms,
but would also require another enzyme. Furthermore, the confor-
mation of the IYD active site accommodating MIT  and DIT is not
likely to allow for additional amino acid residues in the pocket
surrounding the substrate and FMN  as it is stated that there is lit-
tle or no access possible for solvents [25]. Type I iodothyronine
5′-deiodinase (ID1) presents a broader substrate speciﬁcity with
a preference l-thyroxine (T4)  3,3′,5-triiodothyronine (T3) [15],
which is more consistent with our data. The evaluation of the cur-
rently known enzymes being possibly the major responsible for the
deiodination of obestatin reveals future perspectives, which we are
currently investigating.
Although a signiﬁcantly decreased enzymatic degradation with
a more than doubling of its half-life (from 15.7 to 41.5 min) is
observed for mono-iodinated obestatin in liver homogenate when
compared to the native peptide, it is not predictable whether or
not this compound will exhibit either an increased or decreased
activity: e.g. inactivation by antibodies [21] and altered afﬁnity
for its receptor [13,18]. In addition to proteolysis or dehalogena-
tion solely, we also demonstrated the occurrence of combinations
of dehalogenated metabolites or metabolized dehalogenated pep-
tides. As visualized in our scheme (Fig. 4) and conﬁrmed in our
data, deiodination and enzymatic proteolysis processes both occur.
Since these dehalogenated proteolytic fragments were not taken
into account in the estimation of the percentage dehalogenation,
the actual dehalogenated fraction is even higher than our data.
In conclusion, this study demonstrated that the pharmacoki-
netic proﬁle of tyrosine- and histidine-iodinated mouse obestatin
derivatives is not only severely compromised through rapid
B. De Spiegeleer et al. / Peptides 33 (2012) 272–278 277
Fig. 5. Tandem MS  spectrum of the F5 D6 cleavage and single deiodination product (DV
of  689.48. This metabolite arises from both proteolysis and dehalogenation as observed a
d
g
i
tFig. 6. Enzymatic reductive dehalogenation pathways.egradation by systemic proteolytic enzymes, but also by dehalo-
enases. Also, the site-speciﬁcity of the proteases is altered by
ncorporation of iodine atoms. Hence, their use to directly predict
he in vivo pharmacokinetics of unmodiﬁed peptide is questionable.GIKLSGAQYQQHI1GRAL-NH2), eluting at 31.1 min, with a selected parent m/z value
fter incubation of (2,5-diiodo-H19)-obestatin during 20 min  in mouse plasma.
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